Paeds SAQs · allergy-and-immunology
Immunoglobulin replacement and antimicrobial prophylaxis — formative SAQs
Formative SAQs on confirming the indication for immunoglobulin replacement, choosing the route around the family and the trough goal, dosing to outcome, and layering antimicrobial prophylaxis in antibody-deficient children.
On this page & tools
Target exams
SAQ 1 (10)
A six-year-old boy with X-linked agammaglobulinaemia has been on intravenous immunoglobulin since infancy, given every four weeks in a hospital two hours from his home. He has had three proven pneumonias in the past year despite a trough IgG that sits in the lower half of the normal range. His family finds the travel and the missed school increasingly difficult. [3] [2]
a) What are the four structured questions you must ask before simply raising the dose, and why is the trough alone an incomplete target? (3 marks) [2]
b) Discuss the relative pharmacokinetic and practical advantages of switching this child to home subcutaneous immunoglobulin, and the evidence that supports it. (3 marks) [5] [8]
c) Outline a plan to dose this child's regimen to his clinical outcome rather than to a trough number alone, including the role of antimicrobial prophylaxis. (2 marks) [2] [6]
d) Describe the lung surveillance and the family capacity assessment that belong in the revised plan. (2 marks) [3] [8]
You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References6Show ledgerHide ledger
- [1]Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol, 2015.PMID 26371839
- [2]Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol, 2017.PMID 28041678
- [3]Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol, 2006.PMID 16580469
- [5]Suez D, Stein M, Gupta S, et al. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20% in Patients with Primary Immunodeficiency Diseases in North America. J Clin Immunol, 2016.PMID 27582171
- [6]Joud Hajjar, Nguyen AL, Constantine G, et al. Prophylactic Antibiotics Versus Immunoglobulin Replacement in Specific Antibody Deficiency. J Clin Immunol, 2020.PMID 31758281
- [8]Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol, 2012.PMID 22730009